A Phase 4 interventional study of Fractional co2 laser and Exosomes in Atrophic Acne Scar, sponsored by October 6 University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by October 6 University · Phase 4, Interventional, and Treatment
October 6 University is the lead sponsor of 142 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Skin lesions other than acne scars.
Applied topical exosomes on half of the face after fractional co2 laser
Device: Fractional co2 laser · Biological: Exosomes
Hyaluronic acid applied topically after treating the opposite have of the face with fractional co2 laser
Device: Fractional co2 laser · Drug: Hyaluronic Acid skin booster
Transepidermal drug delivery through fractional co2 laser
Topical application of exosomes immediately following fractional carbon dioxide (CO2) laser therapy.
Hyaluronic acid based skin booster applied after fractional co2 laser immediately
Change in Post-Acne Atrophic Scar Severity Score
Quantitative assessment of post-acne atrophic scars (including shape, depth, and number) evaluated on a split-face model using the Goodman and Baron Scale. Scores range from 1 (mild) to 4 (severe), where lower scores indicate clinical improvement.
Time frame: Baseline and 3 months post-treatment
Percentage of Participants Experiencing Clinical Efficacy
Efficacy measured by investigator-rated aesthetic improvement using a standard clinical photograph evaluation.
Time frame: 3 months post-treatment
Number of Participants with Treatment-Related Adverse Events
Evaluation of safety and tolerability based on the incidence, severity, and duration of reported adverse skin reactions (such as prolonged erythema, edema, hyperpigmentation, or scarring) following the application of exosomes versus skin boosters.
Time frame: From day of treatment through 3 months post-treatment
Correlation Between Participant Age and Clinical Response Rate
Statistical correlation evaluating if the patient's age (measured in years) influences the degree of scar improvement achieved by either topical intervention.
Time frame: 3 months post-treatment
Correlation Between Acne Scar Duration and Treatment Efficacy
Statistical evaluation comparing the duration of active post-acne scarring (measured in years since onset) against the overall improvement score.
Time frame: 3 months post-treatment
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
Ran from Jun 2025 to primary completion in Sep 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.